CMS Finalizes Controversial Biosimilars Payment Rule
This article was originally published in Scrip
Executive Summary
Ignoring the objections by several lawmakers and various lobbying groups, the Centers for Medicare & Medicaid Services (CMS) late last week finalized a rule it proposed in July that would lump biosimilars referenced on the same innovator into the same Medicare Part B reimbursement rate.